Your browser doesn't support javascript.
loading
What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?
Wallin, Anders; Alladi, Suvarna; Black, Sandra E; Chen, Christopher; Greenberg, Steven M; Gustafson, Deborah; Isaacs, Jeremy D; Jokinen, Hanna; Kalaria, Raj; Mok, Vincent; Pantoni, Leonardo; Pasquier, Florence; Roman, Gustavo C; Rosenberg, Gary A; Schmidt, Reinhold; Smith, Eric E; Hainsworth, Atticus H.
Afiliação
  • Wallin A; Institute of Neuroscience and Physiology, University of Gothenburg; and Memory Clinic, Sahlgrenska, University Hospital, Gothenburg, Sweden.
  • Alladi S; National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Black SE; Department of Medicine (Neurology), Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON, Canada.
  • Chen C; Memory Aging and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Greenberg SM; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Gustafson D; Department of Neurology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA.
  • Isaacs JD; St George's University Hospitals NHS Foundation Trust, London, UK.
  • Jokinen H; Division of Neuropsychology, HUS Neurocenter, Helsinki University Hospital and University of Helsinki; and Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Kalaria R; Institute of Neuroscience Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK.
  • Mok V; Lui Che Woo Institute of Innovative Medicine,Lui Che Woo Institute of Innovative Medicine, Gerald Choa Neuroscience Centre, Division of Neurology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Pantoni L; Stroke and Dementia Lab, Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy.
  • Pasquier F; Univ Lille, Inserm 1172, CHU Lille, Labex DistALZ, Licend 59000 Lille, France.
  • Roman GC; Methodist Neurological Institute, Houston, Texas 77030, USA.
  • Rosenberg GA; Center for Memory and Aging, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  • Schmidt R; Department of Neurology, Medical University Graz, Graz, Austria.
  • Smith EE; Cumming School of Medicine, University of Calgary, Calgary, Canada.
  • Hainsworth AH; Molecular and Clinical Sciences Research Centre, St George's University of London, Mailpoint J-0B, Cranmer Terrace, London SW17 0RE, UK.
Cereb Circ Cogn Behav ; 3: 100044, 2022.
Article em En | MEDLINE | ID: mdl-36324416
•Controversial registration of aducanumab for Alzheimer's Disease•Aducanumab is the subject of post-licensing observational studies aiming to follow the effects of the drug•Given the high prevalence of cerebrovascular pathology it is important that these studies do not ignore vascular cognitive disorders•The studies may give detailed phenotyping data that may lead to knowledge of targets for treatments of patients with vascular cognitive disorders.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article